ALDEN, an algorithm for assessment of drug causality in stevens-johnson syndrome and toxic epidermal necrolysis: Comparison with case-control analysis

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 1, 2010, Pages 60-68

  Sassolas, B ^a,b   Haddad, C ^b   Mockenhaupt, M ^c   Dunant, A ^b,d   Liss, Y ^c   Bork, K ^e   Haustein, U F ^f   Vieluf, D ^g   Roujeau, J C ^b   Le Louet, H ^b  

^a CHU MORVAN   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^g Fackklinikum Borkum ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ALLOPURINOL; AMINOPENICILLIN; ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMOTRIGINE; LEVOTHYROXINE; MACROLIDE; NEVIRAPINE; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PHENOBARBITAL; PHENYTOIN; QUINOLONE DERIVATIVE; SERTRALINE; SULFAMETHOXAZOLE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VASODILATOR AGENT;

ALGORITHM; ARTICLE; CASE CONTROL STUDY; CAUSAL ATTRIBUTION; COMPARATIVE STUDY; CORRELATION ANALYSIS; DRUG SURVEILLANCE PROGRAM; HUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ALGORITHMS; CASE-CONTROL STUDIES; EPIDERMAL NECROLYSIS, TOXIC; EUROPE; FRANCE; HUMANS; PHARMACEUTICAL PREPARATIONS; PROBABILITY; PRODUCT SURVEILLANCE, POSTMARKETING; RECURRENCE; REPRODUCIBILITY OF RESULTS; STEVENS-JOHNSON SYNDROME; TIME FACTORS;

EID: 77953811466     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.252     Document Type: Article

References (28)

1. Macedo, A.F., Marques, F.B., Ribeiro, C.F. & Teixeira, F. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiol. Drug Saf. 14, 885-890 (2005).
2. Irey, N.S. Diagnostic problems in drug-induced diseases. Ann. Clin. Lab. Sci. 6, 272-277 (1976).
3. Edwards, I.R., Lindquist, M., Wiholm, B.E. & Napke, E. Quality criteria for early signals of possible adverse drug reactions. Lancet 336, 156-158 (1990).
4. Clark, J.A., Klincewicz, S.L. & Stang, P.E. Spontaneous adverse event signaling methods: classifcation and use with health care treatment products. Epidemiol. Rev. 23, 191-210 (2001).
5. Arimone, y. et al. A new method for assessing drug causation provided agreement with experts' judgment. J. Clin. Epidemiol. 59,308-314 (2006).
6. Macedo, A.F., Marques, F.B. & Ribeiro, C.F. Can decisional algorithms replace global introspection in the individual causality assessment of spontaneously reported ADRs? Drug Saf. 29, 697-702 (2006).
7. Meyboom, R.H., Hekster, y.A., Egberts, A.C., Gribnau, F.W. & Edwards, I.R. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf. 17, 374-389 (1997).
8. Roujeau, J.C. & Stern, R.S. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331, 1272-1285 (1994).
9. Bastuji-Garin, S., Rzany, B., Stern, R.S., Shear, N.H., Naldi, L. & Roujeau, J.C. Clinical classifcation of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129, 92-96(1993).
10. Paquet, P. & Piérard, G.E. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am. J. Dermatopathol. 19, 127-132 (1997).
11. Schneck, J., Fagot, J.P., Sekula, P., Sassolas, B., Roujeau, J.C. & Mockenhaupt, M. Efects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J. Am. Acad. Dermatol. 58, 33-40 (2008).
12. Garcia-Doval, I., LeCleach, L., Bocquet, H., Otero, X.L. & Roujeau, J.C. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch. Dermatol. 136, 323-327 (2000).
13. Kaufman, D.W. & Shapiro, S. Epidemiological assessment of drug-induced disease. Lancet 356, 1339-1343 (2000).
14. Roujeau, J.C. et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333, 1600-1607 (1995).
15. Mockenhaupt, M. et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol. 128, 35-44 (2008).
16. EU project focus. RegiSCAR project: the newsletter of the rare disease task force http://www.orpha.net/actor/EuropaNews/2006/060124.html (2006).
17. Guillaume, J.C., Roujeau, J.C., Revuz, J., Penso, D. & Touraine, R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch. Dermatol. 123, 1166-1170 (1987).
18. Naranjo, C.A. et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30, 239-245 (1981).
19. Nassif, A. et al. Drug specifc cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. 118, 728-733 (2002).
20. Paquet, P., Paquet, F., Al Saleh, W., Reper, P., Vanderkelen, A. & Piérard, G.E. Immunoregulatory efector cells in drug-induced toxic epidermal necrolysis. Am. J. Dermatopathol. 22, 413-417 (2000).
21. Ajayi, F.O., Sun, H. & Perry, J. Adverse drug reactions: a review of relevant factors. J. Clin. Pharmacol. 40, 1093-1101 (2000).
22. Roujeau, J.C., Chosidow, O., Saiag, P. & Guillaume, J.C. Toxic epidermal necrolysis (Lyell syndrome). J. Am. Acad. Dermatol. 23, 1039-1058 (1990).
23. Auquier-Dunant, A., Mockenhaupt, M., Naldi, L., Correia, O., Schröder, W. & Roujeau, J.C.; SCAR Study Group. Severe Cutaneous Adverse Reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch. Dermatol. 138, 1019-1024 (2002).
24. Hung, S.I. et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16, 297-306 (2006).
25. Lonjou, C. et al.; RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to fve high-risk drugs. Pharmacogenet. Genomics 18, 99-107 (2008).
26. Rzany, B. et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J. Clin. Epidemiol. 49, 769-773 (1996).
27. Bégaud, B., Evreux, J.C., Jouglard, J. & Lagier, G. [Imputation of the unexpected or toxic efects of drugs. Actualization of the method used in France]. Therapie 40, 111-118 (1985).
28. Benichou, J. Attributable risk. In Encyclopedia of Epidemiologic Methods (eds. Gail, M.H. & Benichou, J.) 50-63 (John Wiley & Sons, New york, 2000).